EGFR and pancreatic neoplasm: miR-146a inhibits cell invasion in pancreatic cancer via inhibition of EGFR and NF-kB pathways [30], weakens the metastatic potential in breast cancer [31] and reduces epithelial-mesenchymal transition of esophageal carcinoma [32].